Peerless Peptides

Oxytocin

Endogenous cyclic nonapeptide hormone with Cys-1/Cys-6 disulfide bridge

Oxytocin is the endogenous nonapeptide hormone of the posterior pituitary, structure Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 with an intramolecular disulfide bridge between Cys-1 and Cys-6. Synthetic oxytocin is the active ingredient in Pitocin (NDA 018261), FDA-approved for obstetric indications since 1962. Vincent du Vigneaud at Cornell University Medical College reported the sequence and the first total chemical synthesis in 1953 (the first peptide hormone ever synthesized), work recognized by the 1955 Nobel Prize in Chemistry.

Available for laboratory research use only.

2-Day Fast Shipping

>99% Purity

Ships from Florida

USA Made & Tested

Choose your supply

Quantity

Independent Lab Results

The most comprehensive testing panel in research peptide commerce. Every batch is independently verified by ILS Laboratories — an ISO/IEC 17025 and PJLA-accredited facility in San Diego, CA.

  • Identity
  • Purity (HPLC)
  • Endotoxin (USP <85>)
  • Sterility (USP <71>)
  • Heavy metals (ICP-MS per USP <233>)
View Certificate of Analysis Program

Biochemical Profile

CAS Number
50-56-6
Molecular Formula
C43H66N12O12S2
Molecular Weight
1007.19 g/mol
Purity
≥99% (HPLC-UV (214-220 nm; Tyr-2 detection at 280 nm))
PubChem CID
439302
Amino Acid Sequence
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Cys-1 / Cys-6 disulfide bridge)

Receptor Pharmacology and Endogenous Physiology

Oxytocin has been characterized as the cognate ligand of the oxytocin receptor (OXTR), a class A G-protein-coupled receptor encoded on human chromosome 3p25. OXTR couples predominantly to Gαq/11, activating phospholipase C, generating inositol trisphosphate and diacylglycerol, mobilizing intracellular calcium, and activating protein kinase C[1]. In uterine and mammary smooth muscle, the resulting calcium transient drives contraction; in central neurons, OXTR signaling has been associated with modulation of neuronal excitability and downstream pathways including MAPK/ERK, β-arrestin recruitment, and indirect signaling through dopaminergic, serotonergic, and GABAergic systems.

Oxytocin and arginine vasopressin (AVP) differ at only two positions in the nonapeptide backbone (Ile-3 to Phe-3 and Leu-8 to Arg-8), yet those substitutions shift receptor selectivity substantially. At pharmacologically relevant concentrations, oxytocin binds vasopressin receptors V1a, V1b (V3), and V2; the V1b receptor is particularly cross-reactive. Disentangling OXTR-specific from AVP-receptor-mediated effects in behavioral neuroscience requires receptor-selective antagonists that are not consistently available across research settings[1].

OXTR distribution has been mapped across peripheral tissues (myometrium, mammary myoepithelium, vascular endothelium, kidney, gut) and central regions (amygdala, prefrontal cortex, nucleus accumbens, hippocampus, brainstem). Species differences in central OXTR distribution are substantial. Comparative receptor mapping of the monogamous prairie vole versus the polygamous montane vole anchored the comparative behavioral neurobiology of pair-bonding research program led by Insel, Carter, and Young[2][3].

Endogenous oxytocin is synthesized in magnocellular hypothalamic neurons of the supraoptic and paraventricular nuclei as part of the 125-amino-acid pre-pro-hormone OXT/neurophysin-I (UniProt P01178). The mature nonapeptide is cleaved from neurophysin I during axonal transport to the posterior pituitary and released into the systemic circulation in pulsatile fashion in response to cervical and vaginal distention (the Ferguson reflex) and to suckling stimuli. Plasma half-life is approximately 1-6 minutes (commonly reported 3.2 minutes by intravenous infusion in nonpregnant adults); rapid clearance occurs via hepatic and renal first-pass metabolism and via placental and uterine oxytocinase during pregnancy.

The pharmacokinetics of intranasal oxytocin administration are contested in the published research literature. Leng and Ludwig (2016) estimated that approximately 0.005 percent of an intranasally administered dose reaches the cerebrospinal fluid within one hour, a finding that complicates mechanistic interpretation of the entire intranasal-oxytocin behavioral research literature[4]. Quintana et al. (2020) reported that oxytocin-induced decreases in amygdala perfusion observed after intranasal administration were entirely explained by oxytocin increases in systemic circulation following both intranasal and intravenous routes, supporting peripheral-feedback rather than direct nose-to-brain mechanisms[5].

Research Applications

Obstetric Research and the FDA-Approved Indication

Uterine smooth muscle is the best-characterized peripheral target for oxytocin and the foundation of the obstetric Pitocin indication. Myometrial OXTR mRNA expression at term is approximately 100-fold higher than mid-gestation values, which is the molecular basis for the term-pregnancy responsiveness of the uterus to circulating oxytocin and for the dose adjustments required when Pitocin is administered intravenously. OXTR signaling generates phasic uterine contractions through Gαq/PLC/IP3/calcium mobilization in myometrial smooth muscle[1].

Pitocin (oxytocin injection USP, NDA 018261, originally Parke-Davis) has been FDA-approved since 1962. The approved indications are induction or stimulation of labor at term when medical or obstetric indication is present and vaginal delivery is otherwise contraindicated, augmentation of dysfunctional labor (hypotonic uterine action), control of postpartum bleeding or hemorrhage following placental delivery, and adjunctive therapy in management of incomplete or inevitable abortion. The on-label evidence base spans more than six decades of clinical use, hundreds of randomized trials of dosing regimens and adjunctive uses, and continuous post-marketing surveillance.

The WHO CHAMPION trial (Widmer et al., NEJM 2018) enrolled approximately 29,645 women across 23 hospitals in 10 countries comparing heat-stable carbetocin (a long-acting 1-deamino oxytocin analog) with oxytocin for prevention of postpartum hemorrhage after vaginal birth[6]. Heat-stable carbetocin demonstrated non-inferiority to oxytocin for the primary composite outcome. The WHO added heat-stable carbetocin to the Essential Medicines List in 2019 for settings where oxytocin quality cannot be assured or refrigeration is unavailable.

Lactation and Mammary Myoepithelium

Mammary myoepithelial contraction in response to circulating oxytocin is the canonical milk-letdown or milk-ejection reflex, originally characterized by Ott and Scott in 1910 to 1911 and confirmed across countless subsequent rodent and human studies. Suckling stimulates rapid bursts of magnocellular oxytocin firing in the supraoptic and paraventricular nuclei; circulating oxytocin then acts on OXTR-expressing myoepithelial cells surrounding the mammary alveoli, causing contraction that ejects milk into the duct system[7].

An intranasal Syntocinon product (oxytocin nasal spray, Sandoz/Novartis) was originally FDA-approved circa 1960 for facilitation of initial postpartum milk ejection. The product was withdrawn from the US market by Novartis in 1997 for commercial reasons rather than safety findings. The intranasal Syntocinon withdrawal removed the only US-approved intranasal oxytocin product from commerce and is one reason the contemporary off-label intranasal-oxytocin research literature operates without an approved formulation as a reference standard.

Mammary biology of oxytocin is the second on-label indication area where the published evidence base is substantial, mechanism is unambiguous, the dosing-versus-effect relationship is well-characterized, and the clinical readout is directly measurable. The mammary-myoepithelium evidence sits in the same evidentiary regime as the uterine-contraction evidence and is categorically distinct from the off-label intranasal-for-social-behavior research literature.

Autism Research and the SOARS-B Phase 2 Trial

Intranasal oxytocin has been investigated as an off-label candidate in autism spectrum disorder across approximately 40 randomized controlled trials over the 2000s to 2020s. Earlier small studies reported variable signals on social cognition, emotion recognition, repetitive behaviors, and quality of life (Anagnostou et al. 2012; Watanabe et al. 2015; Parker et al. 2017; Yamasue et al. 2020)[8][9][10][11]. These early signals motivated progressively larger trials.

The largest of those trials was the SOARS-B study (Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors), sponsored by the Autism Centers of Excellence network and led by Linmarie Sikich at Duke University Medical Center with funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NCT01944046). Design: multicenter, randomized, double-blind, placebo-controlled Phase 2 trial. Population: 290 children and adolescents aged 3 to 17 years with confirmed autism spectrum disorder, recruited across multiple US sites. Intervention: intranasal oxytocin administered across 24 weeks under a published trial protocol, with a 24-week open-label extension. Primary outcome: least-squares mean change from baseline on the Aberrant Behavior Checklist modified Social Withdrawal subscale (ABC-mSW)[12].

Result: no significant difference between oxytocin and placebo groups (p approximately 0.503); oxytocin and placebo groups exhibited nearly identical changes on all primary and secondary endpoints. The trial was published as Sikich et al., NEJM 2021, and the accompanying NEJM editorial (Howes and Bhandari) characterized the result as a setback for the autism intranasal-oxytocin hypothesis[13]. The SOARS-B trial design (large n, prospective registration, prespecified outcome, multicenter, well-funded, conducted by autism-specialist sites) is the kind of trial that should have detected a real effect of the magnitude implied by earlier small-N positive studies.

Social-Behavior Research and the Replication Crisis

The intranasal-oxytocin social-behavior research literature is one of the most-discussed examples of the replication crisis in behavioral neuroscience. The seminal report by Kosfeld, Heinrichs, Zak, Fischbacher, and Fehr (Nature 2005) described intranasal oxytocin as increasing monetary transfers in a behavioral economics trust game; the paper has accumulated more than 5,000 citations[14]. Subsequent attempts at direct or conceptual replication have not consistently reproduced the headline finding.

Nave, Camerer, and McCullough (Perspectives on Psychological Science 2015) conducted a critical review of the oxytocin-and-trust literature and concluded that the published evidence does not support a robust effect[15]. Declerck et al. (Nature Human Behaviour 2020) reported a preregistered double-blind placebo-controlled replication with greater than 95 percent power: no effect of intranasal oxytocin on trusting behavior in minimal social contact conditions[16]. Walum, Waldman, and Young (Biological Psychiatry 2016) published a meta-methodological critique estimating that statistical power for typical intranasal-oxytocin behavioral studies is often below 20 percent, that the field exhibits striking effect-size heterogeneity across laboratories studying ostensibly the same effect, and that flexibility in analytic decisions inflates the false-positive rate substantially[17].

The broader pattern (high-profile small-N finding, repeated non-replication, continued citation as if uncontested) is a textbook case of the replication-crisis dynamics in social neuroscience.

Psychiatric and Neuropsychiatric Research

Intranasal oxytocin has been investigated as an off-label adjunct across multiple psychiatric indications. Sabe et al. (International Journal of Neuropsychopharmacology 2021) performed a systematic review and meta-analysis of nine randomized controlled trials of intranasal oxytocin for negative symptoms of schizophrenia[18]. The aggregate finding was no consistent effect on negative or positive symptoms across pooled analyses, with a dosing-stratified meta-analytic comparison suggesting possible signal at the highest doses tested but the authors cautioning against firm conclusions given trial heterogeneity and small sample sizes.

Intranasal oxytocin has been tested as an adjunct to psychotherapy for posttraumatic stress disorder (mixed signals across small randomized trials), for depression (no consistent effect across small randomized trials), for substance use disorders including alcohol, opioids, and stimulants (mixed signals on craving and withdrawal endpoints), for borderline personality disorder (small randomized trials with mixed signals), and for obesity (Phase 2 trials with modest weight-related findings in some studies). The consistent pattern across these literatures has been promising small-N findings followed by inconsistent replication at larger scale.

A separate Phase 2 program (FOXY, Canadian and US sites, approximately 152 patients) tested daily versus intermittent intranasal oxytocin for apathy in frontotemporal dementia, with reported behavioral signals on Neuropsychiatric Inventory subscales. None of these off-label psychiatric or neuropsychiatric indications hold FDA approval for oxytocin administration, and all human use in these contexts is investigational.

Replication, Clinical Status, and Approved-Drug Distinction

Three independent methodology problems compound when reading the off-label intranasal-oxytocin literature. First, low statistical power in typical individual studies (often n=20 to n=80 per arm, often with many secondary outcomes and subgroup analyses). Second, uncertain central pharmacology: Leng and Ludwig (2016) argued that the entire premise of intranasal-oxytocin behavioral research rests on weakly supported pharmacokinetic data, with their estimate of approximately 0.005 percent CSF penetration falling far below the in vitro concentrations at which OXTR binding becomes pharmacologically relevant[4]. Third, receptor cross-reactivity at vasopressin V1a, V1b, and V2 receptors confounds the inference from observed behavioral effects to OXTR-mediated action.

The SOARS-B trial (Sikich et al., NEJM 2021, n=290) was the largest, longest, best-powered, and most rigorously designed test of the autism intranasal-oxytocin hypothesis published to date[13]. The trial met every standard of contemporary clinical research: NIH-funded, multicenter, prospectively registered, prespecified primary outcome, double-blind, placebo-controlled, 24-week dosing, broad age range, real-world heterogeneous autism population. The result was unambiguously null on primary and secondary endpoints. The trial does not rule out a small responder-phenotype effect, but it does indicate that the magnitude implied by earlier small-N positive trials is not present in a real-world autism spectrum disorder population at the doses and durations the field had converged on as plausible.

The Pitocin obstetric record sits in a categorically different evidentiary regime. Intravenous oxytocin acts on myometrial OXTR at directly measurable physiological doses with directly measurable physiological endpoints (uterine contraction frequency and amplitude, plasma oxytocin levels). The mechanism is unambiguous. The dosing-versus-effect curve is well-characterized across six decades of obstetric pharmacology. The clinical endpoint (successful induction, controlled postpartum bleeding) is hard, measurable, and clinically consequential. More than six decades of randomized trials, post-marketing surveillance, and clinical experience cumulatively form one of the strongest evidence bases for any peptide pharmaceutical[6]. These two evidentiary settings (the on-label obstetric record and the off-label intranasal social-behavior record) should not be conflated in scientific framing.

Reconstitution & Storage

Recommended Diluent
Bacteriostatic water (0.9% benzyl alcohol) or sterile saline
Storage (lyophilized)
-20°C, dry, dark, 24-36 months
Storage (reconstituted)
2-8°C, use within 14 days
Shelf Life
24-36 months lyophilized

Research References

  1. [1] Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629-683. PMID:11274341
  2. [2] Insel TR, Young LJ. The neurobiology of attachment. Nat Rev Neurosci. 2001;2(2):129-136. PMID:11252992
  3. [3] Young LJ, Wang Z. The neurobiology of pair bonding. Nat Neurosci. 2004;7(10):1048-1054. PMID:15452576
  4. [4] Leng G, Ludwig M. Intranasal oxytocin: myths and delusions. Biol Psychiatry. 2016;79(3):243-250. PMID:26049207
  5. [5] Quintana DS, Lischke A, Grace S, Scheele D, Ma Y, Becker B. Advances in the field of intranasal oxytocin research: lessons learned and future directions. Nat Commun. 2020;11(1):1160. PMID:32127535
  6. [6] Widmer M, Piaggio G, Nguyen TMH, et al. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth (WHO CHAMPION). N Engl J Med. 2018;379(8):743-752. PMID:29949469
  7. [7] du Vigneaud V, Ressler C, Trippett S. The sequence of oxytocin. J Biol Chem. 1953;205(2):949-957. PMID:13129278
  8. [8] Anagnostou E, Soorya L, Chaplin W, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012;3(1):16. PMID:23216716
  9. [9] Watanabe T, Kuroda M, Kuwabara H, et al. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain. 2015;138(11):3400-3412. PMID:25599577
  10. [10] Parker KJ, Oztan O, Libove RA, et al. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proc Natl Acad Sci USA. 2017;114(30):8119-8124. PMID:28747667
  11. [11] Yamasue H, Okada T, Munesue T, et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Mol Psychiatry. 2020;25(8):1849-1858. PMID:30217978
  12. [12] Sikich L et al. NCT01944046 — Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (SOARS-B). ClinicalTrials.gov. Phase 2, multicenter, randomized, double-blind, placebo-controlled, n=290; primary endpoint ABC-mSW. Trial completed 2017.
  13. [13] Sikich L, Kolevzon A, King BH, McDougle CJ, et al. Intranasal oxytocin in children and adolescents with autism spectrum disorder. N Engl J Med. 2021;385(16):1462-1473. PMID:34644471
  14. [14] Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005;435(7042):673-676. PMID:15931222
  15. [15] Nave G, Camerer C, McCullough M. Does oxytocin increase trust in humans? A critical review of research. Perspect Psychol Sci. 2015;10(6):772-789. PMID:26581735
  16. [16] Declerck CH, Boone C, Pauwels L, Vogt B, Fehr E. A registered replication study on oxytocin and trust. Nat Hum Behav. 2020;4(6):646-655. PMID:32514040
  17. [17] Walum H, Waldman ID, Young LJ. Statistical and methodological considerations for the interpretation of intranasal oxytocin studies. Biol Psychiatry. 2016;79(3):251-257. PMID:26210057
  18. [18] Sabe M, Zhao N, Crippa A, Strauss GP, Kaiser S. Intranasal oxytocin for negative symptoms of schizophrenia: systematic review, meta-analysis, and dose-response meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2021;24(8):601-614. PMID:33871018

Scientific Journal Author

Vincent du Vigneaud, PhD

Department of Biochemistry, Cornell University Medical College (originating oxytocin synthesis program)

Landmark Publications

  • du Vigneaud V, Ressler C, Trippett S. The sequence of oxytocin. J Biol Chem. 1953;205(2):949-957. (PMID 13129278)
  • du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc. 1953;75(19):4879-4880.
  • du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG. The synthesis of oxytocin. J Am Chem Soc. 1954;76(12):3115-3121. doi:10.1021/ja01641a004.
  • 1955 Nobel Prize in Chemistry, awarded to Vincent du Vigneaud for the first total synthesis of a peptide hormone (https://www.nobelprize.org/prizes/chemistry/1955/vigneaud/facts/).

Dr. du Vigneaud is independently cited here as the originating researcher of oxytocin synthesis at Cornell University Medical College and as the 1955 Nobel laureate in Chemistry for that work. Dr. du Vigneaud died in 1978. There is no affiliation or commercial relationship between Dr. du Vigneaud's estate, Cornell University, the Nobel Foundation, and Peerless Peptides.

Frequently Asked Questions